1. Essential Updates in Atopic Dermatitis:

5. Pathogenesis and the Future of AD Treatment

6. Epidemiology of AD

7. ISAAC Global Prevalence of Eczema by Region

8. AD and Other Skin Allergies US Centers for Disease Control

9. AD Prevalence -- United States

10. Diagnosis and Clinical Presentation

11. Differential Diagnosis of AD

12. Severity of AD

13. Severity of AD Comparison of Physician and Patient Ratings

14. Risk Factors for AD Atopic March Hypothesis

15. Risk Factors for AD Family History

16. FLG Mutations, Filaggrin, and Epidermal Barrier Function

17. Pathogenesis of AD

18. Pathogenesis: Immune Dysregulation

20. AD and Quality of Life

21. AD and QoL Adults

22. AD and Sleep Disturbances Children

23. Comorbidities -- Obesity and Metabolic Syndrome Pediatric Patients

24. Comorbidities -- Cardiovascular Disease Adult Patients

25. Comorbidities: Mental Illness Pediatric Patients

26. Comorbidities -- ADHD Adult Patients

27. Comorbidities -- Mental Illness Adult Patients

28. Current Standard of Care

29. Targeted Agents for AD

30. Dupilumab: Phase 3 Data

31. Nemolizumab: Phase 2 Data

32. Other Targeting Agents Under Investigation for Moderate to Severe AD

33. Concluding Remarks

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)